Employees: 1,298
Size Beijing Aerospace Changfeng (600855.SS) is a China Health Care company (Medical Specialties) with a market value of $738M, the 2770th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.96 on 18 Nov 2026.
Performance Over six months the shares fell 44.4%, against -13.5% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 10.2% over the last twelve months (peer median +9.1%); the operating margin is -18.9% (peer median 13.3%).
Valuation It trades at 4.5× enterprise value to sales against a peer median of 3.1× (5th most expensive of 21).
Capital Return on invested capital runs 17.5 points below its cost of capital (9.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.03B | CN¥1.25B | CN¥1.15B | CN¥1.37B | CN¥1.80B |
| Revenue growth | — | +8% | -16% | -24% | — |
| Gross profit | CN¥251M | CN¥201M | CN¥190M | CN¥211M | CN¥435M |
| EBITDA | n/a | -CN¥103M | -CN¥206M | -CN¥181M | CN¥55.8M |
| Net income | -CN¥164M | -CN¥172M | -CN¥246M | -CN¥235M | CN¥5.48M |
| Free cash flow | -CN¥45.9M | -CN¥41.8M | -CN¥80.0M | -CN¥93.2M | -CN¥157M |
| Capital expenditure | CN¥24.7M | CN¥27.2M | CN¥67.8M | CN¥89.7M | CN¥80.6M |
| Total debt | CN¥177M | CN¥239M | CN¥343M | CN¥375M | CN¥387M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600855.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.2% | -8.5% | 8th lowest of 21 |
| 6-month return | -44.4% | -13.5% | lowest of 21 |
| Distance from 52-week high | -63.5% | -37.6% | lowest of 21 |
| Revenue growth (TTM) | -10.2% | +9.1% | 3rd lowest of 21 |
| Operating margin | -18.9% | 13.3% | 3rd lowest of 21 |
| EV / Sales | 4.5× | 3.1× | 5th most expensive of 21 |
| ROIC minus cost of capital | -17.5 pp | +1.4 pp | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | 4.5× | n/a | n/a |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 1.8× | -1.5% | +15.6% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 5.8× | 17.1% | +24.2% |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 0.6× | -10.8% | +12.4% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 1.7× | 20.3% | -0.2% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 2.8× | -1.9% | +11.8% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | 1.5× | n/a | n/a |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 7.8× | 27.9% | +9.9% |
| Caina Technology 301122.SZ | China | $721M | +36% | +61% | 0% | 7.7× | n/a | n/a |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 2.3× | 7.9% | -10.2% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 3.6× | 3.8% | +105.8% |
| Doctorglasses Chain 300622.SZ | China | $710M | -22% | +6% | 14% | 3.1× | -3.4% | +15.7% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 1.2× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 3.2× | 9.6% | +15.5% |
| SWS Hemodialysis Care 688410.SS | China | $706M | -11% | +31% | 19% | 3.6× | 16.2% | +25.9% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | 2.6× | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 3.6× | 21.3% | +13.2% |
| Japan Lifeline 7575.T | Japan | $703M | +34% | +6% | 19% | 1.7× | -9.5% | +2.9% |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $700M | -25% | +35% | 21% | 3.6× | -3.3% | +23.5% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | 4.3× | n/a | n/a |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $697M | +148% | -14% | 3% | 10.3× | 31.8% | -0.6% |